<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39327654</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>The Assessment of Anti-SARS-CoV-2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta-Analysis of COVID-19 Vaccine Clinical Trial Studies.</ArticleTitle><Pagination><StartPage>e2579</StartPage><MedlinePgn>e2579</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2579</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">The COVID-19 pandemic spread rapidly throughout the world and caused millions of deaths globally. Several vaccines have been developed to control the COVID-19 pandemic and reduce the burden it placed on public health. This study aimed to assess the efficacy of different vaccine platforms in inducing potent antibody responses. Moreover, the seroconversion rate and common side effects of vaccine platforms were evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This meta-analysis included clinical trials of COVID-19 vaccines that met the eligibility criteria. Electronic databases (including PubMed, Scopus, and Web of Science) and Google Scholar search engine were searched for eligible studies. Regarding the methodological heterogeneity between the included studies, we selected a random-effects model. The geometric mean ratio (GMR) was chosen as the effect size for this meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1838 records identified through screening and after removing duplicate records, the full texts of 1076 records were assessed for eligibility. After the full-text assessment, 56 records were eligible and included in the study. Overall, vaccinated participants had a 150.8-fold increased rate of anti-spike IgG titres compared with the placebo group (GMR = 150.8; 95% CI, 95.9-237.1; I<sup>2</sup> = 100%). Moreover, vaccinated participants had a 37.3-fold increased rate of neutralising antibody titres compared with the placebo group (GMR = 37.3; 95% CI, 28.5-48.7; I<sup>2</sup> = 99%). The mRNA platform showed a higher rate of anti-spike IgG (GMR = 1263.5; 95% CI, 431.1-3702.8; I<sup>2</sup> = 99%), while neutralising antibody titres were higher in the subunit platform (GMR = 53.4; 95% CI, 32.8-87.1; I<sup>2</sup> = 99%) than in other platforms. Different vaccine platforms showed different rates of both anti-spike IgG and neutralising antibody titres with interesting results. The seroconversion rate of anti-spike IgG and neutralising antibody titres was more than 98% in the vaccinated participants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Inactivated and subunit vaccines produced a high percentage of neutralising antibodies and had a low common adverse reaction rate compared to other platforms. In this regard, subunit and inactivated vaccines can still be used as the main vaccine platforms for effectively controlling infections with high transmission rates.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirzakhani</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8831-3006</Identifier><AffiliationInfo><Affiliation>Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayat</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dashti</LastName><ForeName>Mohammadreza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kashmar School of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahmasebi</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostamtabar</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaeili Gouvarchin Ghaleh</LastName><ForeName>Hadi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8562-2295</Identifier><AffiliationInfo><Affiliation>Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amani</LastName><ForeName>Jafar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">anti‐spike IgG</Keyword><Keyword MajorTopicYN="N">neutralising antibody</Keyword><Keyword MajorTopicYN="N">spike glycoprotein</Keyword><Keyword MajorTopicYN="N">trails</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327654</ArticleId><ArticleId IdType="doi">10.1002/rmv.2579</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S.‐M. Hsieh, M.‐C. Liu, Y.‐H. Chen, et al., “Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide‐Adjuvanted SARS‐CoV‐2 S‐2P Protein Vaccine MVC‐COV1901: Interim Results of a Large‐Scale, Double‐Blind, Randomised, Placebo‐Controlled Phase 2 Trial in Taiwan,” Lancet Respiratory Medicine 9, no. 12 (2021): 1396–1406, https://doi.org/10.1016/s2213‐2600(21)00402‐1.</Citation></Reference><Reference><Citation>Web3, https://extranet.who.int/pqweb/vaccines/vaccinescovid‐19‐vaccine‐eul‐issued.</Citation></Reference><Reference><Citation>M. D. Tanriover, H. L. Doğanay, M. Akova, et al., “Efficacy and Safety of an Inactivated Whole‐Virion SARS‐CoV‐2 Vaccine (CoronaVac): Interim Results of a Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Trial in Turkey,” Lancet 398, no. 10296 (2021): 213–222, https://doi.org/10.1016/s0140‐6736(21)01429‐x.</Citation></Reference><Reference><Citation>K. J. Chappell, F. L. Mordant, Z. Li, et al., “Safety and Immunogenicity of an MF59‐Adjuvanted Spike Glycoprotein‐Clamp Vaccine for SARS‐CoV‐2: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 Trial,” Lancet Infectious Diseases 21, no. 10 (2021): 1383–1394, https://doi.org/10.1016/s1473‐3099(21)00200‐0.</Citation></Reference><Reference><Citation>G.‐L. Chen, X.‐F. Li, X.‐H. Dai, et al., “Safety and Immunogenicity of the SARS‐CoV‐2 ARCoV mRNA Vaccine in Chinese Adults: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 Trial,” Lancet Microbe 3, no. 3 (2022): e193–e202, https://doi.org/10.1016/s2666‐5247(21)00280‐9.</Citation></Reference><Reference><Citation>H. Yu, L. J. Worrall, T. Berger, et al., “Identification of an Optimized Receptor‐Binding Domain Subunit Vaccine Against SARS‐CoV‐2,” Journal of Immunology 211, no. 6 (2023): 981–993, https://doi.org/10.4049/jimmunol.2300282.</Citation></Reference><Reference><Citation>L. Du, Y. Yang, and X. Zhang, “Neutralizing Antibodies for the Prevention and Treatment of COVID‐19,” Cellular and Molecular Immunology 18, no. 10 (2021): 2293–2306, https://doi.org/10.1038/s41423‐021‐00752‐2.</Citation></Reference><Reference><Citation>M. Sadarangani, A. Marchant, and T. R. Kollmann, “Immunological Mechanisms of Vaccine‐Induced Protection Against COVID‐19 in Humans,” Nature Reviews Immunology 21, no. 8 (2021): 475–484, https://doi.org/10.1038/s41577‐021‐00578‐z.</Citation></Reference><Reference><Citation>M. Asano, H. Okada, Y. Itoh, et al., “Immunogenicity and Safety of AZD1222 (ChAdOx1 nCoV‐19) Against SARS‐CoV‐2 in Japan: A Double‐Blind, Randomized Controlled Phase 1/2 Trial,” International Journal of Infectious Diseases 114 (2022): 165–174, https://doi.org/10.1016/j.ijid.2021.10.030.</Citation></Reference><Reference><Citation>J. R. Barrett, S. Belij‐Rammerstorfer, C. Dold, et al., “Phase 1/2 Trial of SARS‐CoV‐2 Vaccine ChAdOx1 nCoV‐19 With a Booster Dose Induces Multifunctional Antibody Responses,” Nature Medicine 27, no. 2 (2021): 279–288, https://doi.org/10.1038/s41591‐020‐01179‐4.</Citation></Reference><Reference><Citation>F. X. Heinz and K. Stiasny, “Distinguishing Features of Current COVID‐19 Vaccines: Knowns and Unknowns of Antigen Presentation and Modes of Action,” NPJ Vaccines 6, no. 1 (2021): 104, https://doi.org/10.1038/s41541‐021‐00369‐6.</Citation></Reference><Reference><Citation>Y. Chen, X. Zhao, H. Zhou, H. Zhu, S. Jiang, and P. Wang, “Broadly Neutralizing Antibodies to SARS‐CoV‐2 and Other Human Coronaviruses,” Nature Reviews Immunology 23, no. 3 (2023): 189–199, https://doi.org/10.1038/s41577‐022‐00784‐3.</Citation></Reference><Reference><Citation>K. Ali, G. Berman, H. Zhou, et al., “Evaluation of mRNA‐1273 SARS‐CoV‐2 Vaccine in Adolescents,” New England Journal of Medicine 385, no. 24 (2021): 2241–2251, https://doi.org/10.1056/nejmoa2109522.</Citation></Reference><Reference><Citation>N. Al Kaabi, A. Oulhaj, F. I. Al Hosani, et al., “The Incidence of COVID‐19 Infection Following Emergency Use Authorization of BBIBP‐CORV Inactivated Vaccine in Frontline Workers in the United Arab Emirates,” Scientific Reports 12, no. 1 (2022): 490, https://doi.org/10.1038/s41598‐021‐04244‐1.</Citation></Reference><Reference><Citation>N. A. Kaabi, Y. K. Yang, L. F. Du, et al., “Safety and Immunogenicity of a Hybrid‐Type Vaccine Booster in BBIBP‐CorV Recipients in a Randomized Phase 2 Trial,” Nature Communications 13, no. 1 (2022): 3654, https://doi.org/10.1038/s41467‐022‐31379‐0.</Citation></Reference><Reference><Citation>L.‐L. Ma, Y.‐Y. Wang, Z.‐H. Yang, D. Huang, H. Weng, and X.‐T. Zeng, “Methodological Quality (Risk of Bias) Assessment Tools for Primary and Secondary Medical Studies: What Are They and Which Is Better?,” Military Medical Research 7 (2020): 1–11, https://doi.org/10.1186/s40779‐020‐00238‐8.</Citation></Reference><Reference><Citation>S. M. Bueno, K. Abarca, P. A. González, et al., “Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile,” Clinical Infectious Diseases 75, no. 1 (2022): e792–e804, https://doi.org/10.1093/cid/ciab823.</Citation></Reference><Reference><Citation>F. Vanhoutte, W. Liu, R. T. Wiedmann, et al., “Safety and Immunogenicity of the Measles Vector‐Based SARS‐CoV‐2 Vaccine Candidate, V591, in Adults: Results from a Phase 1/2 Randomised, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Trial,” EBioMedicine 75 (2022): 103811, https://doi.org/10.1016/j.ebiom.2021.103811.</Citation></Reference><Reference><Citation>E. E. Walsh, R. W. Frenck, A. R. Falsey, et al., “Safety and Immunogenicity of Two RNA‐Based Covid‐19 Vaccine Candidates,” New England Journal of Medicine 383, no. 25 (2020): 2439–2450, https://doi.org/10.1056/nejmoa2027906.</Citation></Reference><Reference><Citation>C. Y. Wang, K.‐P. Hwang, H.‐K. Kuo, et al., “A Multitope SARS‐CoV‐2 Vaccine Provides Long‐Lasting B Cell and T Cell Immunity Against Delta and Omicron Variants,” Journal of Clinical Investigation 132, no. 10 (2022), https://doi.org/10.1172/jci157707.</Citation></Reference><Reference><Citation>S. Xia, Y. Zhang, Y. Wang, et al., “Safety and Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine, BBIBP‐CorV: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1/2 Trial,” Lancet Infectious Diseases 21, no. 1 (2021): 39–51, https://doi.org/10.1016/s1473‐3099(20)30831‐8.</Citation></Reference><Reference><Citation>S. Yang, Y. Li, L. Dai, et al., “Safety and Immunogenicity of a Recombinant Tandem‐Repeat Dimeric RBD‐Based Protein Subunit Vaccine (ZF2001) Against COVID‐19 in Adults: Two Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 and 2 Trials,” Lancet Infectious Diseases 21, no. 8 (2021): 1107–1119, https://doi.org/10.1016/s1473‐3099(21)00127‐4.</Citation></Reference><Reference><Citation>K. Zakarya, L. Kutumbetov, M. Orynbayev, et al., “Safety and Immunogenicity of a QazCovid‐In® Inactivated Whole‐Virion Vaccine Against COVID‐19 in Healthy Adults: A Single‐Centre, Randomised, Single‐Blind, Placebo‐Controlled Phase 1 and an Open‐Label Phase 2 Clinical Trials With a 6 Months Follow‐Up in Kazakhstan,” EClinicalMedicine 39 (2021): 101078, https://doi.org/10.1016/j.eclinm.2021.101078.</Citation></Reference><Reference><Citation>Y. Liao, Y. Li, R. Pei, et al., “Safety and Immunogenicity of a Recombinant Interferon‐Armed RBD Dimer Vaccine (V‐01) for COVID‐19 in Healthy Adults: A Randomized, Double‐Blind, Placebo‐Controlled, Phase I Trial,” Emerging Microbes &amp; Infections 10, no. 1 (2021): 1589–1597, https://doi.org/10.1080/22221751.2021.1951126.</Citation></Reference><Reference><Citation>Y. Zhang, G. Zeng, H. Pan, et al., “Safety, Tolerability, and Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine in Healthy Adults Aged 18–59 Years: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1/2 Clinical Trial,” Lancet Infectious Diseases 21, no. 2 (2021): 181–192, https://doi.org/10.1016/s1473‐3099(20)30843‐4.</Citation></Reference><Reference><Citation>F. Zhu, P. Jin, T. Zhu, et al., “Safety and Immunogenicity of a Recombinant Adenovirus Type‐5–Vectored Coronavirus Disease 2019 (COVID‐19) Vaccine With a Homologous Prime‐Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double‐Blind, Placebo‐Controlled, Phase 2b Trial,” Clinical Infectious Diseases 75, no. 1 (2022): e783–e791, https://doi.org/10.1093/cid/ciab845.</Citation></Reference><Reference><Citation>F.‐C. Zhu, X.‐H. Guan, Y.‐H. Li, et al., “Immunogenicity and Safety of a Recombinant Adenovirus Type‐5‐Vectored COVID‐19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 2 Trial,” Lancet 396, no. 10249 (2020): 479–488, https://doi.org/10.1016/s0140‐6736(20)31605‐6.</Citation></Reference><Reference><Citation>L. Chu, R. McPhee, W. Huang, et al., “A Preliminary Report of a Randomized Controlled Phase 2 Trial of the Safety and Immunogenicity of mRNA‐1273 SARS‐CoV‐2 Vaccine,” Vaccine 39, no. 20 (2021): 2791–2799, https://doi.org/10.1016/j.vaccine.2021.02.007.</Citation></Reference><Reference><Citation>A. D. Dang, T. D. Vu, H. H. Vu, et al., “Safety and Immunogenicity of an Egg‐Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS‐CoV‐2 Spike: Interim Results of a Randomized, Placebo‐Controlled, Phase 1/2 Trial in Vietnam,” Vaccine 40, no. 26 (2022): 3621–3632, https://doi.org/10.1016/j.vaccine.2022.04.078.</Citation></Reference><Reference><Citation>R. Ella, S. Reddy, W. Blackwelder, et al., “Efficacy, Safety, and Lot‐to‐Lot Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine (BBV152): Interim Results of a Randomised, Double‐Blind, Controlled, Phase 3 Trial,” Lancet 398, no. 10317 (2021): 2173–2184, https://doi.org/10.1016/s0140‐6736(21)02000‐6.</Citation></Reference><Reference><Citation>E. Fadlyana, K. Rusmil, R. Tarigan, et al., “A Phase III, Observer‐Blind, Randomized, Placebo‐Controlled Study of the Efficacy, Safety, and Immunogenicity of SARS‐CoV‐2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia,” Vaccine 39, no. 44 (2021): 6520–6528, https://doi.org/10.1016/j.vaccine.2021.09.052.</Citation></Reference><Reference><Citation>N. Formica, R. Mallory, G. Albert, et al., “Different Dose Regimens of a SARS‐CoV‐2 Recombinant Spike Protein Vaccine (NVX‐CoV2373) in Younger and Older Adults: A Phase 2 Randomized Placebo‐Controlled Trial,” PLoS Medicine 18, no. 10 (2021): e1003769, https://doi.org/10.1371/journal.pmed.1003769.</Citation></Reference><Reference><Citation>P. A. Goepfert, B. Fu, A.‐L. Chabanon, et al., “Safety and Immunogenicity of SARS‐CoV‐2 Recombinant Protein Vaccine Formulations in Healthy Adults: Interim Results of a Randomised, Placebo‐Controlled, Phase 1–2, Dose‐Ranging Study,” Lancet Infectious Diseases 21, no. 9 (2021): 1257–1270, https://doi.org/10.1016/s1473‐3099(21)00147‐x.</Citation></Reference><Reference><Citation>W. Guo, K. Duan, Y. Zhang, et al., “Safety and Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1/2 Trial,” EClinicalMedicine 38 (2021): 101010, https://doi.org/10.1016/j.eclinm.2021.101010.</Citation></Reference><Reference><Citation>M. Haranaka, J. Baber, Y. Ogama, et al., “A Randomized Study to Evaluate Safety and Immunogenicity of the BNT162b2 COVID‐19 Vaccine in Healthy Japanese Adults,” Nature Communications 12, no. 1 (2021): 7105, https://doi.org/10.1038/s41467‐021‐27316‐2.</Citation></Reference><Reference><Citation>A.‐M. Hui, J. Li, L. Zhu, et al., “Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Phase 2 Randomised Clinical Trial,” Lancet Regional Health–Western Pacific 29 (2022): 100586, https://doi.org/10.1016/j.lanwpc.2022.100586.</Citation></Reference><Reference><Citation>F. Hernández‐Bernal, M. C. Ricardo‐Cobas, Y. Martín‐Bauta, et al., “Safety, Tolerability, and Immunogenicity of a SARS‐CoV‐2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1–2 Clinical Trial (ABDALA Study),” EClinicalMedicine 46 (2022): 101383, https://doi.org/10.1016/j.eclinm.2022.101383.</Citation></Reference><Reference><Citation>S. Iwata, T. Sonoyama, A. Kamitani, et al., “Phase 1/2 Clinical Trial of COVID‐19 Vaccine in Japanese Participants: A Report of Interim Findings,” Vaccine 40, no. 27 (2022): 3721–3726, https://doi.org/10.1016/j.vaccine.2022.04.054.</Citation></Reference><Reference><Citation>C. Keech, G. Albert, I. Cho, et al., “Phase 1–2 Trial of a SARS‐CoV‐2 Recombinant Spike Protein Nanoparticle Vaccine,” New England Journal of Medicine 383, no. 24 (2020): 2320–2332, https://doi.org/10.1056/nejmoa2026920.</Citation></Reference><Reference><Citation>A. Khobragade, S. Bhate, V. Ramaiah, et al., “Efficacy, Safety, and Immunogenicity of the DNA SARS‐CoV‐2 Vaccine (ZyCoV‐D): The Interim Efficacy Results of a Phase 3, Randomised, Double‐Blind, Placebo‐Controlled Study in India,” Lancet 399, no. 10332 (2022): 1313–1321, https://doi.org/10.1016/s0140‐6736(22)00151‐9.</Citation></Reference><Reference><Citation>P. S. Kulkarni, C. Padmapriyadarsini, J. Vekemans, et al., “A Phase 2/3, Participant‐Blind, Observer‐Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII‐ChAdOx1 nCoV‐19 (COVID‐19 Vaccine) in Adults in India,” EClinicalMedicine 42 (2021): 101218, https://doi.org/10.1016/j.eclinm.2021.101218.</Citation></Reference><Reference><Citation>J. Li, A. Hui, X. Zhang, et al., “Safety and Immunogenicity of the SARS‐CoV‐2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo‐Controlled, Double‐Blind Phase 1 Study,” Nature Medicine 27, no. 6 (2021): 1062–1070, https://doi.org/10.1038/s41591‐021‐01330‐9.</Citation></Reference><Reference><Citation>J. Li, A.‐M. Hui, X. Zhang, et al., “Immune Persistence and Safety After SARS‐CoV‐2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo‐Controlled, Double‐Blind Phase 1 Trial,” Advances in Therapy 39, no. 8 (2022): 3789–3798, https://doi.org/10.1007/s12325‐022‐02206‐1.</Citation></Reference><Reference><Citation>J. Liu, B. Huang, G. Li, et al., “Immunogenicity and Safety of a 3‐Dose Regimen of a SARS‐CoV‐2 Inactivated Vaccine in Adults: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial,” Journal of Infectious Diseases 225, no. 10 (2022): 1701–1709, https://doi.org/10.1093/infdis/jiab627.</Citation></Reference><Reference><Citation>D. Y. Logunov, I. V. Dolzhikova, D. V. Shcheblyakov, et al., “Safety and Efficacy of an rAd26 and rAd5 Vector‐Based Heterologous Prime‐Boost COVID‐19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia,” Lancet 397, no. 10275 (2021): 671–681, https://doi.org/10.1016/s0140‐6736(21)00234‐8.</Citation></Reference><Reference><Citation>S. A. Madhi, A. L. Koen, A. Izu, et al., “Safety and Immunogenicity of the ChAdOx1 nCoV‐19 (AZD1222) Vaccine Against SARS‐CoV‐2 in People Living With and Without HIV in South Africa: An Interim Analysis of a Randomised, Double‐Blind, Placebo‐Controlled, Phase 1B/2A Trial,” Lancet HIV 8, no. 9 (2021): e568–e580, https://doi.org/10.1016/s2352‐3018(21)00157‐0.</Citation></Reference><Reference><Citation>T. Masuda, K. Murakami, K. Sugiura, S. Sakui, R. P. Schuring, and M. Mori, “A Phase 1/2 Randomised Placebo‐Controlled Study of the COVID‐19 Vaccine mRNA‐1273 in Healthy Japanese Adults: An Interim Report,” Vaccine 40, no. 13 (2022): 2044–2052, https://doi.org/10.1016/j.vaccine.2022.02.030.</Citation></Reference><Reference><Citation>T. Masuda, K. Murakami, K. Sugiura, S. Sakui, R. P. Schuring, and M. Mori, “Safety and Immunogenicity of NVX‐CoV2373 (TAK‐019) Vaccine in Healthy Japanese Adults: Interim Report of a Phase I/II Randomized Controlled Trial,” Vaccine 40, no. 24 (2022): 3380–3388, https://doi.org/10.1016/j.vaccine.2022.04.035.</Citation></Reference><Reference><Citation>T. P. Nguyen, Q. Do, L. T. Phan, et al., “Safety and Immunogenicity of Nanocovax, a SARS‐CoV‐2 Recombinant Spike Protein Vaccine: Interim Results of a Double‐Blind, Randomised Controlled Phase 1 and 2 Trial,” Lancet Regional Health–Western Pacific 24 (2022): 100474, https://doi.org/10.1016/j.lanwpc.2022.100474.</Citation></Reference><Reference><Citation>M. J. Mulligan, K. E. Lyke, N. Kitchin, et al., “Phase I/II Study of COVID‐19 RNA Vaccine BNT162b1 in Adults,” Nature 586, no. 7830 (2020): 589–593, https://doi.org/10.1038/s41586‐020‐2639‐4.</Citation></Reference><Reference><Citation>M. Mohraz, M. Salehi, P. Tabarsi, et al., “Safety and Immunogenicity of an Inactivated Virus Particle Vaccine for SARS‐CoV‐2, BIV1‐CovIran: Findings From Double‐Blind, Randomised, Placebo‐Controlled, Phase I and II Clinical Trials Among Healthy Adults,” BMJ Open 12, no. 4 (2022): e056872, https://doi.org/10.1136/bmjopen‐2021‐056872.</Citation></Reference><Reference><Citation>F.‐Y. Meng, F. Gao, S.‐Y. Jia, et al., “Safety and Immunogenicity of a Recombinant COVID‐19 Vaccine (Sf9 Cells) in Healthy Population Aged 18 Years or Older: Two Single‐Center, Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 and Phase 2 Trials,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 271, https://doi.org/10.1038/s41392‐021‐00692‐3.</Citation></Reference><Reference><Citation>S. Xia, K. Duan, Y. Zhang, et al., “Effect of an Inactivated Vaccine Against SARS‐CoV‐2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials,” JAMA 324, no. 10 (2020): 951–960, https://doi.org/10.1001/jama.2020.15543.</Citation></Reference><Reference><Citation>Y.‐J. Shu, J.‐F. He, R.‐J. Pei, et al., “Immunogenicity and Safety of a Recombinant Fusion Protein Vaccine (V‐01) Against Coronavirus Disease 2019 in Healthy Adults: A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Trial,” Chinese Medical Journal 134, no. 16 (2021): 1967–1976, https://doi.org/10.1097/cm9.0000000000001702.</Citation></Reference><Reference><Citation>H.‐X. Pan, J.‐K. Liu, B.‐Y. Huang, et al., “Immunogenicity and Safety of a Severe Acute Respiratory Syndrome Coronavirus 2 Inactivated Vaccine in Healthy Adults: Randomized, Double‐Blind, and Placebo‐Controlled Phase 1 and Phase 2 Clinical Trials,” Chinese Medical Journal 134, no. 11 (2021): 1289–1298, https://doi.org/10.1097/cm9.0000000000001573.</Citation></Reference><Reference><Citation>J. Sadoff, M. Le Gars, G. Shukarev, et al., “Interim Results of a Phase 1–2a Trial of Ad26. COV2. S Covid‐19 Vaccine,” New England Journal of Medicine 384, no. 19 (2021): 1824–1835, https://doi.org/10.1056/nejmoa2034201.</Citation></Reference><Reference><Citation>J. Pu, Q. Yu, Z. Yin, et al., “The Safety and Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine in Chinese Adults Aged 18–59 Years: A Phase I Randomized, Double‐Blinded, Controlled Trial,” Vaccine 39, no. 20 (2021): 2746–2754, https://doi.org/10.1016/j.vaccine.2021.04.006.</Citation></Reference><Reference><Citation>M. N. Ramasamy, A. M. Minassian, K. J. Ewer, et al., “Safety and Immunogenicity of ChAdOx1 nCoV‐19 Vaccine Administered in a Prime‐Boost Regimen in Young and Old Adults (COV002): A Single‐Blind, Randomised, Controlled, Phase 2/3 Trial,” Lancet 396, no. 10267 (2020): 1979–1993, https://doi.org/10.1016/s0140‐6736(20)32466‐1.</Citation></Reference><Reference><Citation>P. Richmond, L. Hatchuel, M. Dong, et al., “Safety and Immunogenicity of S‐Trimer (SCB‐2019), a Protein Subunit Vaccine Candidate for COVID‐19 in Healthy Adults: A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial,” Lancet 397, no. 10275 (2021): 682–694, https://doi.org/10.1016/s0140‐6736(21)00241‐5.</Citation></Reference><Reference><Citation>J. Y. Song, W. S. Choi, J. Y. Heo, et al., “Safety and Immunogenicity of a SARS‐CoV‐2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With AS03: A Randomised, Placebo‐Controlled, Observer‐Blinded Phase 1/2 Trial,” EClinicalMedicine 51 (2022): 101569, https://doi.org/10.1016/j.eclinm.2022.101569.</Citation></Reference><Reference><Citation>P. Tabarsi, N. Anjidani, R. Shahpari, et al., “Safety and Immunogenicity of SpikoGen®, an Advax‐CpG55. 2‐Adjuvanted SARS‐CoV‐2 Spike Protein Vaccine: A Phase 2 Randomized Placebo‐Controlled Trial in Both Seropositive and Seronegative Populations,” Clinical Microbiology and Infection 28, no. 9 (2022): 1263–1271, https://doi.org/10.1016/j.cmi.2022.04.004.</Citation></Reference><Reference><Citation>M. E. Toledo‐Romani, M. García‐Carmenate, L. Verdecia‐Sánchez, et al., “Safety and Immunogenicity of Anti‐SARS‐CoV‐2 Heterologous Scheme With SOBERANA 02 and SOBERANA Plus Vaccines: Phase IIb Clinical Trial in Adults,” Med 3, no. 11 (2022): 760–773, https://doi.org/10.1016/j.medj.2022.08.001.</Citation></Reference><Reference><Citation>Z. Wu, Y. Hu, M. Xu, et al., “Safety, Tolerability, and Immunogenicity of an Inactivated SARS‐CoV‐2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1/2 Clinical Trial,” Lancet Infectious Diseases 21, no. 6 (2021): 803–812, https://doi.org/10.1016/s1473‐3099(20)30987‐7.</Citation></Reference><Reference><Citation>G. Zeng, Q. Wu, H. Pan, et al., “Immunogenicity and Safety of a Third Dose of CoronaVac, and Immune Persistence of a Two‐Dose Schedule, in Healthy Adults: Interim Results from Two Single‐Centre, Double‐Blind, Randomised, Placebo‐Controlled Phase 2 Clinical Trials,” Lancet Infectious Diseases 22, no. 4 (2022): 483–495, https://doi.org/10.1016/s1473‐3099(21)00681‐2.</Citation></Reference><Reference><Citation>Web1, https://ourworldindata.org/covid‐vaccinations.</Citation></Reference><Reference><Citation>C. Zeng, C. Zhang, P. G. Walker, and Y. Dong, “Formulation and Delivery Technologies for mRNA Vaccines,” in mRNA Vaccines, eds. D. Yu and B. Petsch (Cham: Springer International Publishing, 2022), 71–110.</Citation></Reference><Reference><Citation>Web, https://www.cdc.gov/coronavirus/2019‐ncov/vaccines/different‐vaccines/how‐they‐work.html.</Citation></Reference><Reference><Citation>Web2, https://www.pfizer.com/news/articles/understanding_six_types_of_vaccine_technologies.</Citation></Reference><Reference><Citation>I. P. Trougakos, E. Terpos, H. Alexopoulos, et al., “Adverse Effects of COVID‐19 mRNA Vaccines: The Spike Hypothesis,” Trends in Molecular Medicine 28, no. 7 (2022): 542–554, https://doi.org/10.1016/j.molmed.2022.04.007.</Citation></Reference><Reference><Citation>Y. Zlotnik, A. Gadoth, I. Abu‐Salameh, A. Horev, R. Novoa, and G. Ifergane, “Case Report: Anti‐LGI1 Encephalitis Following COVID‐19 Vaccination,” Frontiers in Immunology 12 (2022): 813487, https://doi.org/10.3389/fimmu.2021.813487.</Citation></Reference><Reference><Citation>K. N. Al, Y. Zhang, S. Xia, et al., “Effect of 2 Inactivated SARS‐CoV‐2 Vaccines on Symptomatic COVID‐19 Infection in Adults: A Randomized Clinical Trial,” JAMA 326, no. 1 (2021): 35–45.</Citation></Reference><Reference><Citation>D. R. Burton, “Advancing an HIV Vaccine; Advancing Vaccinology,” Nature Reviews Immunology 19, no. 2 (2019): 77–78, https://doi.org/10.1038/s41577‐018‐0103‐6.</Citation></Reference><Reference><Citation>J. R. Shapiro, B. Hodgins, H. E. Hendin, et al., “Needle‐Free Delivery of Influenza Vaccine Using the Med‐Jet® H4 Is Efficient and Elicits the Same Humoral and Cellular Responses as Standard IM Injection: A Randomized Trial,” Vaccine 37, no. 10 (2019): 1332–1339, https://doi.org/10.1016/j.vaccine.2019.01.039.</Citation></Reference><Reference><Citation>E. J. Wherry and D. H. Barouch, “T Cell Immunity to COVID‐19 Vaccines,” Science 377, no. 6608 (2022): 821–822, https://doi.org/10.1126/science.add2897.</Citation></Reference><Reference><Citation>J. Zhao, J. Zhao, A. K. Mangalam, et al., “Airway Memory CD4+ T Cells Mediate Protective Immunity Against Emerging Respiratory Coronaviruses,” Immunity 44, no. 6 (2016): 1379–1391, https://doi.org/10.1016/j.immuni.2016.05.006.</Citation></Reference><Reference><Citation>K. McMahan, J. Yu, N. B. Mercado, et al., “Correlates of Protection Against SARS‐CoV‐2 in Rhesus Macaques,” Nature 590, no. 7847 (2021): 630–634, https://doi.org/10.1038/s41586‐020‐03041‐6.</Citation></Reference><Reference><Citation>U. Laserson, F. Vigneault, D. Gadala‐Maria, et al., “High‐Resolution Antibody Dynamics of Vaccine‐Induced Immune Responses,” Proceedings of the National Academy of Sciences 111, no. 13 (2014): 4928–4933, https://doi.org/10.1073/pnas.1323862111.</Citation></Reference><Reference><Citation>P. J. Hotez, M. E. Bottazzi, and D. B. Corry, The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine‐Induced Immune Enhancement (France: Elsevier, 2020), 165–167.</Citation></Reference><Reference><Citation>Y. Dou, B. Fu, R. Sun, et al., “Influenza Vaccine Induces Intracellular Immune Memory of Human NK Cells,” PLoS One 10, no. 3 (2015): e0121258, https://doi.org/10.1371/journal.pone.0121258.</Citation></Reference><Reference><Citation>H. Kouhpayeh and H. Ansari, “Adverse Events Following COVID‐19 Vaccination: A Systematic Review and Meta‐Analysis,” International Immunopharmacology 109 (2022): 108906, https://doi.org/10.1016/j.intimp.2022.108906.</Citation></Reference><Reference><Citation>M. Jeyanathan, S. Afkhami, F. Smaill, M. S. Miller, B. D. Lichty, and Z. Xing, “Immunological Considerations for COVID‐19 Vaccine Strategies,” Nature Reviews Immunology 20, no. 10 (2020): 615–632, https://doi.org/10.1038/s41577‐020‐00434‐6.</Citation></Reference><Reference><Citation>F. Bayani, N. S. Hashkavaei, S. Arjmand, et al., “An Overview of the Vaccine Platforms to Combat COVID‐19 With a Focus on the Subunit Vaccines,” Progress in Biophysics and Molecular Biology 178 (2023): 32–49, https://doi.org/10.1016/j.pbiomolbio.2023.02.004.</Citation></Reference><Reference><Citation>Ç Deniz, B. Altunan, and A. Ünal, “Anti‐GAD Encephalitis Following COVID‐19 Vaccination: A Case Report,” Archives of Neuropsychiatry 60, no. 3 (2023): 283.</Citation></Reference><Reference><Citation>C. McShane, C. Kiat, J. Rigby, and Ó Crosbie, “The mRNA COVID‐19 Vaccine—A Rare Trigger of Autoimmune Hepatitis?,” Journal of Hepatology 75, no. 5 (2021): 1252–1254, https://doi.org/10.1016/j.jhep.2021.06.044.</Citation></Reference><Reference><Citation>S. R. Gadi, P. A. Brunker, H. Al‐Samkari, et al., “Severe Autoimmune Hemolytic Anemia Following Receipt of SARS‐CoV‐2 mRNA Vaccine,” Transfusion 61, no. 11 (2021): 3267–3271, https://doi.org/10.1111/trf.16672.</Citation></Reference><Reference><Citation>M. Rojas, Y. Rodríguez, Y. Acosta‐Ampudia, et al., “Autoimmunity is a Hallmark of Post‐COVID Syndrome,” Journal of Translational Medicine 20, no. 1 (2022): 1–5, https://doi.org/10.1186/s12967‐022‐03328‐4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>